CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials-Reference-Cited by-同舟云学术

CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials

Published:2018-11-07 Issue:7 Volume:93 Page:1246-1252
ISSN:1522-1946
Container-title:Catheterization and Cardiovascular Interventions
language:en
Short-container-title:Catheter Cardiovasc Interv

Author:

Kheiri Babikir¹^ORCID,Osman Mohammed²,Abdalla Ahmed¹,Haykal Tarek¹,Pandrangi Pranay V.³,Chahine Adam¹,Ahmed Sahar¹,Osman Khansa¹,Bachuwa Ghassan¹,Hassan Mustafa¹,Bhatt Deepak L.⁴^ORCID

Affiliation:

1. Department of Internal Medicine; Hurley Medical Center/Michigan State University; Flint Michigan

2. Division of Cardiology; West Virginia University School of Medicine; Morgantown West Virginia

3. Department of Internal Medicine; Spectrum Health/Michigan State University; Grand Rapids Michigan

4. Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School; Boston Massachusetts

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ccd.27949/fullpdf

Reference29 articles.

1. The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery;Beinema;Mol Diagn Ther,2007

2. Role of genetic testing in patients undergoing percutaneous coronary intervention;Moon;Expert Rev Clin Pharmacol,2018

3. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial;Notarangelo;J Am Coll Cardiol,2018

4. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study;Collet;Lancet,2009

5. Identification and biological activity of the active metabolite of clopidogrel;Savi;Thromb Haemost,2000

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of smoking status on clopidogrel responsiveness in patients with coronary artery disease who undergo percutaneous coronary intervention;F1000Research;2023-08-23

2. The impact of smoking status on clopidogrel responsiveness in patients with coronary artery disease who undergo percutaneous coronary intervention;F1000Research;2023-04-05

3. Effectiveness of atorvastatin on the levels of nitric oxide and serum lipids in coronary artery disease patients: Response to clopidogrel resistance;F1000Research;2023-04-05

4. CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD);American Heart Journal;2022-12

5. Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events;European Heart Journal - Cardiovascular Pharmacotherapy;2022-07-15